Phathom reports preliminary Q4 2025 revenue $57-58M; full year $174.5-175.5M; VOQUEZNA surpasses 1M prescriptions

Phathom Pharmaceuticals, Inc.

2025-FY EPS reported -$3.03 revenue$175,110,000

Q4 2025 net revenues expected ~$57-58M; full year 2025 net revenues ~$174.5-175.5M.
GAAP operating expenses Q4: ~$59-61M; non-GAAP (excl. stock-based comp) ~$51-53M.
Cash and equivalents ~$130M as of 12/31/25; net cash usage in Q4 ~$6M.
VOQUEZNA products surpassed 1 million prescriptions dispensed in U.S. during Q4.
Operating profitability (excl. stock-based comp) anticipated in second half of 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.